Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03584009
Title A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy
Acronym Veronica
Recruitment Terminated
Gender female
Phase Phase II
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | GBR | DEU | CAN | AUS


No variant requirements are available.